A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients

BACKGROUND: Cytomegalovirus (CMV) is a complication of allogeneic haematopoietic cell transplantation (allo-HCT). ASP0113, a DNA-based vaccine, contains two plasmids encoding human CMV glycoprotein B and phosphoprotein 65 (pp65). We assessed ASP0113 in CMV-seropositive allo-HCT recipients. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Ljungman, Per, Bermudez, Arancha, Logan, Aaron C., Kharfan-Dabaja, Mohamed A., Chevallier, Patrice, Martino, Rodrigo, Wulf, Gerald, Selleslag, Dominik, Kakihana, Kazuhiko, Langston, Amelia, Lee, Dong-Gun, Solano, Carlos, Okamoto, Shinichiro, Smith, Larry R., Boeckh, Michael, Wingard, John R., Cywin, Beth, Fredericks, Christine, Lademacher, Christopher, Wang, Xuegong, Young, James, Maertens, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020145/
https://www.ncbi.nlm.nih.gov/pubmed/33842870
http://dx.doi.org/10.1016/j.eclinm.2021.100787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020145/
https://www.ncbi.nlm.nih.gov/pubmed/33842870
http://dx.doi.org/10.1016/j.eclinm.2021.100787

Ejemplares similares